- Bristol Myers Squibb and Pfizer announce a direct-to-patient purchasing option for Eliquis, offering over 40% discount.
- The new program targets uninsured, underinsured, and self-paying patients across the U.S. and Puerto Rico.
- Eligible patients can access the discounted Eliquis through Eliquis 360 Support starting September 8, 2025.
The Bristol Myers Squibb (BMY, Financial) and Pfizer (PFE) Alliance is set to launch a new direct-to-patient option for accessing Eliquis® (apixaban) via their Eliquis 360 Support program. This initiative aims to provide uninsured, underinsured, or self-paying patients with significant out-of-pocket cost savings, offering the medication at a discounted rate exceeding 40% off the current list price. This direct purchasing option, available from September 8, 2025, will provide a streamlined and transparent access point for this vital medication.
Eliquis, the leading oral anticoagulant prescribed in the United States, is used daily by millions of Americans. The new program will ensure that eligible patients with an Eliquis prescription can purchase and receive the medication via direct shipping throughout all 50 states and Puerto Rico. This initiative demonstrates the Alliance's commitment to improving patient access and affordability while supporting comprehensive health outcomes.
Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb, emphasized the importance of this program, stating, "The BMS-Pfizer Alliance is committed to increasing patient access and affordability. Eliquis is the nation’s number one prescribed oral anticoagulant, providing important benefits to patients and the healthcare system. This program passes more savings directly to patients and demonstrates our continued focus on innovative solutions that prioritize access to care."
The Eliquis 360 Support program is designed to assist patients with health education and navigating their prescription insurance coverage. This program is expected to augment the affordability and accessibility of Eliquis, which has already contributed to $3 billion in estimated healthcare cost savings and avoidance for every 100,000 patients treated.
